Mylan Faces Suit Over Orapred ANDA

Law360, New York (December 17, 2010, 3:58 PM EST) -- Shionogi Pharma Inc. and Cima Labs Inc. have filed a patent infringement suit over Mylan Inc.'s bid to introduce a generic version of anti-inflammatory Orapred ODT in various strengths.

Mylan confirmed Friday that the suit had been filed Dec. 9 in the U.S. District Court for the District of Delaware in response to the drugmaker's abbreviated new drug application for three different strengths of prednisolone sodium phosphate orally disintegrating tablets, a corticosteroid prescribed for the treatment of certain endocrine conditions, among other uses, and sold under...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.